AUS
NZ
UK
CA
USA
IND
Highlights
- Short interest in Encompass Health Co. increased by 7.8% in November.
- Hedge funds and institutional investors hold 97.25% of Encompass Health’s shares.
- Encompass Health reported a 11.9% year-over-year revenue growth.
Encompass Health Corp, a leading player in the healthcare sector, recently saw a rise in short interest, signaling shifting market dynamics. As one of the notable NYSE Healthcare Stocks, Encompass Health continues to experience strong institutional backing and impressive revenue growth, alongside a quarterly dividend declaration. This update explores the latest developments impacting the company.
Encompass Health Co. (NYSE:EHC) Sees Increase in Short Interest and Positive
Encompass Health Co. ,a prominent provider of post-acute healthcare services, has witnessed an uptick in short interest during the month of November. The company’s short interest as of November 15th totaled 1,100,000 shares, a 7.8% increase from the previous month. This rise signals growing interest in short positions despite the company’s positive performance in recent quarters. With an average daily trading volume of 622,400 shares, the days-to-cover ratio now stands at 1.8 days, representing a modest 1.1% of the company’s outstanding shares being sold short.
Analyst Upgrades Support Positive Outlook for Encompass Health
Encompass Health has been the focus of several positive analyst updates. UBS Group raised its price target from $100 to $110 and maintained a "buy" rating. Other analysts have echoed this sentiment, with Stephens reaffirming an "overweight" rating and a $105 target, while Truist Financial increased its price objective to $116 from $108. Barclays also raised its target from $109 to $116, showing strong market confidence. Nine analysts have rated the stock with a buy rating, and two have given a strong buy rating. The consensus target price is $107.11, indicating continued optimism for the company.
Institutional Ownership Remains Strong
Institutional interest in Encompass Health has been robust, with several hedge funds and institutional investors adjusting their positions. UMB Bank n.a. significantly increased its holdings by 387.7%, while V Square Quantitative Management LLC raised its stake by 53%. Other investors such as Avior Wealth Management LLC and Benjamin F. Edwards & Company Inc. also bought into the company during recent quarters. Institutional investors now control 97.25% of the company’s stock, reinforcing the belief in Encompass Health’s long-term growth prospects.
Stock Performance and Market Metrics
Encompass Health’s stock opened at $102.38 on a recent trading day. The stock has been steadily performing with a 50-day moving average of $98.16 and a 200-day moving average of $91.45. With a market capitalization of $10.31 billion, the company’s P/E ratio stands at 24.73, and its PEG ratio is 1.36, reflecting a solid valuation in the healthcare sector. The company has a quick ratio of 1.04 and a current ratio of 1.04, maintaining a stable liquidity position. Encompass Health’s stock has experienced a 52-week low of $64.15 and a high of $104.55, reflecting its ongoing market volatility.
Financial Performance and Earnings Results
Encompass Health recently reported strong quarterly earnings. For the period ending October 28th, the company posted earnings of $1.03 per share, surpassing analysts’ estimates of $0.94 by $0.09. This was accompanied by a year-over-year revenue increase of 11.9%, reaching $1.35 billion, which also exceeded expectations. The company’s net margin stood at 8.10%, with a return on equity of 17.60%. Analysts forecast Encompass Health will post earnings of $4.29 per share for the current year, suggesting continued growth.
Dividend Announcement
Encompass Health also declared a quarterly dividend, set to be paid on January 15th. Shareholders of record by January 2nd will receive a $0.17 per share dividend, with an annualized yield of 0.66%. The company’s payout ratio stands at 16.43%, indicating a conservative approach to dividend distributions.
Encompass Health Co. has shown strong performance with rising short interest and continued institutional confidence. Despite the increase in short positions, the company remains a key player in the healthcare sector, with solid financial results and a positive outlook from analysts. The increase in short interest does not overshadow the company’s ongoing success and commitment to providing post-acute healthcare services across the U.S. and Puerto Rico.
